TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Quality of episodic memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients with positive MRI in positive VQ-SPECT group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients with positive MRI in negative VQ-SPECT group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of Low Cardiac Output Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective response (partial and complete)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bioavailability of (poly)phenols and microbial metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Tolerant Patients Off SRL Therapy With Normal Liver Biochemistry and Graft Histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of postoperative oral pain medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Rating Scale (NRS) scale improvement
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Sedentary behavior (minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food cravings (total and specific)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post Operative Ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SCDIC Framework of Interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Canadian Occupational Performance Measure Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in World Health Organization-Quality of Life Brief (WHO-QoL BREF) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Short Form 36 (SF 36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Shoulder function and pain (ASES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in xerostomia measured by visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBBDQs Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients with new vascular events (stroke)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Platelet inhibition ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients With Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Impression of Change (PGIC) Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavior Rating Inventory for Executive Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners Continuous Performance Test III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Period prevalence of deep vein thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Dopamine receptor binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the concentration-time Curve for idronoxil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal observed concentration for idronoxil levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum observed concentration for idronoxil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spontaneous delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Increase in heart rate with standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of chronic renal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fugl Meyer assessment (upper extremity) of motor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immunoglobulin G (IgG) antibody serum titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: switched immunoglobulin G (swIgG) B memory cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immunoglobulin M (IgM) B memory cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Undetectable Serum HCV RNA or 2-log Decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Affiliation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Time between withdrawal of orotracheal tube and POV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain score: verbal simple scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain score: visual number scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of positive urine protein test changing to the negative result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The ratio of positive to negative urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The decrease of 24-hour urine protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in accuracy of LVEF estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Comprehensive Frailty Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Clinical Laboratory Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reporting One or More Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of artificial ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects completing the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Medications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Agreement between SOC test and Spartan COVID-19 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SUDEP
Endpoint domain: Mortality/survival
Primary endpoint: change in variations of the T and B cell repertoire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bioequivalence interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of heart disease or stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of lenalidomide
Endpoint domain: Adverse events/effects
Primary endpoint: measured cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Experience Acute GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experience Moderate to Severe Chronic GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of grade 3 & 4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in Left Ventricular Thrombus Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numerical Heart to Mediastinum (H/M) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: EMG gaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Leucine Disposal Rate (LDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With >=4 Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hSBA Geometric Mean Titers (GMTs) for Each of the 2 Primary Test Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical sensitivity of the Samsung LABGEO IVD-A20 CHF Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical specificity of the Samsung LABGEO IVD-A20 CHF Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve from time 0 to the time of last quantifiable plasma concentration (AUC[0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of negative Xpert test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychiatric Inventory Irritability-Aggression Domains Composite Measure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of lower urinary tract symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Average Steps Per Day at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Steps Per Day at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Berg Balance at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to 6 Months in Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to 3 Months in Lower Body Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to 6 Months in Lower Body Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of α-linolenic acid in milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in spinal height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal volumetric bone mineral density (vBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Bowel Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improved vaginal moisture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ZAK expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problem solving
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: sensitivity and specificity of Xpert MTB/RIF Ultra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance of lymph node dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: spontaneous physical activity energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Short Physical Performance Battery (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDNF DNA demethylation in percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gastrointestinal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of episodes of desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Confirmed Progressive Multifocal Leukoencephalopathy (PML)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Serious Adverse Events of Other Serious Opportunistic Infections (OIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load of HIV-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukocyte telomere length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of bowel movements/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardio-metabolic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 25OH-Vitamin D Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Sustained Clinical Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters of levetiracetam and ucb L057
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal Anastomosis Fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Esophageal fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical Site Infection in Breast Reconstructions
Endpoint domain: Adverse events/effects
Primary endpoint: Skin Necrosis in Head and Neck Reconstruction
Endpoint domain: Adverse events/effects
Primary endpoint: Mastectomy Skin Necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Breast Implant Extrusion
Endpoint domain: Adverse events/effects
Primary endpoint: positive lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Stop Signal Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Pre-Post in Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pre-Post Cognitive Affective Battery- Negative Urgency Subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fall events
Endpoint domain: Adverse events/effects
Primary endpoint: antibacterial activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OC symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission time in intermediate care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target bifurcation failure (TBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical muscle tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of repeated self-harming acts including suicide attempts
Endpoint domain: Adverse events/effects
Primary endpoint: normalized plasma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Oral Health-related Quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Word List Test (memory, recall, recognition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of the surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of pneumonia complicating stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical features of aortic dissection and aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement of endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first event of diarrhea due to vaccine-preventable ETEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive outcome in high-risk neuroblastoma patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average annual conversion rate from MCI to AD
Endpoint domain: Mortality/survival
Primary endpoint: Change in tumor necrosis factor alpha (TNF alpha) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in malondialdehyde levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Androxal excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pain 6h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pain 12 hours postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutic Cure Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who developed ventilator-associated events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: All cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Prostate Cancer
Endpoint domain: Mortality/survival
Primary endpoint: status of the resection margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: abdominal adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diameter responses of retinal arterioles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Positivity Ratings of Social Images
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Steady state pharmacokinetics of atazanavir/ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate in supraclavicular lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of VX-659, TEZ, and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Pre-Dose Concentration (Ctrough) of VX-659, TEZ, and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of VX-659, TEZ, and IVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily PHN scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early healing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR12 Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients experiencing treatment-related and treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time of physiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Assessment of Cancer Therapy Colorectal
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Manifestations of Psychological Well-being Measurement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of Framingham risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Utilizing ITP Therapies for First-line Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase dim-light melatonin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cognition as Measured by the RBANS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive Function as Measured by the D-KEFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in LVESV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Steady state plasma metformin pharmacokinetics (PK) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady state plasma DTG PK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state plasma metformin PK parameters in Period 2 as compared to those in Period 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left-ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes